Northland Capmk Reduces Earnings Estimates for MiMedx Group

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Equities research analysts at Northland Capmk reduced their FY2025 earnings per share estimates for MiMedx Group in a report issued on Thursday, February 27th. Northland Capmk analyst C. Byrnes now expects that the company will post earnings per share of $0.28 for the year, down from their previous estimate of $0.30. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

MDXG has been the topic of several other reports. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th. StockNews.com lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $12.00.

MiMedx Group Trading Down 1.1 %

Shares of MiMedx Group stock traded down $0.09 on Monday, hitting $8.00. 527,445 shares of the company traded hands, compared to its average volume of 711,695. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.18 billion, a PE ratio of 14.55 and a beta of 1.97. The stock's 50 day moving average price is $8.63 and its 200-day moving average price is $7.75. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $10.14.

Remove Ads

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting analysts' consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

Hedge Funds Weigh In On MiMedx Group

Large investors have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY boosted its position in MiMedx Group by 0.5% during the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock valued at $45,082,000 after acquiring an additional 22,131 shares in the last quarter. Cannell Capital LLC boosted its position in MiMedx Group by 1.1% during the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after purchasing an additional 40,235 shares in the last quarter. First Light Asset Management LLC bought a new stake in MiMedx Group during the fourth quarter valued at about $32,168,000. Geode Capital Management LLC grew its stake in MiMedx Group by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock valued at $16,518,000 after purchasing an additional 44,254 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in MiMedx Group by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock worth $17,360,000 after purchasing an additional 280,327 shares in the last quarter. Institutional investors own 79.15% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.